CNBX Pharmaceuticals Inc.
CNBX Pharmaceuticals Inc. (CNBX) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
cnbx · pe ratio · data through Jun 10, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
CNBX Pharmaceuticals Inc.You CNBX | $0M | N/A | — | — |
 Acura Pharmaceuticals, Inc. ACUR | $0M | N/A | — | -$0.02 |
 Affymax, Inc. AFFY | $0M | N/A | — | -$0.39 |
 Endonovo Therapeutics, Inc. ENDV | $0M | N/A | — | -$0.00 |
 Filament Health Corp. FLHLF | $0M | N/A | — | -$0.02 |
 GeneLink, Inc. GNLKQ | $0M | N/A | — | -$0.01 |
 Itoco Inc. ITMC | $0M | N/A | — | -$0.01 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for CNBX Pharmaceuticals Inc. (CNBX) measures how much investors pay for each dollar of the company's trailing earnings. CNBX's current PE ratio of N/A is calculated by dividing its stock price of $0.00 by its TTM earnings per share of —.
Frequently asked questions
CNBX pe ratio · 6 questionsCNBX's current PE ratio is N/A as of 2026-06-10, based on a stock price of $0.00 and TTM EPS of —. Data sourced from Financial Modeling Prep via CNBX's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · CNBX Pharmaceuticals Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-10